Status:
RECRUITING
SNV1521 in Participants with Advanced Solid Tumors
Lead Sponsor:
Synnovation Therapeutics, Inc.
Conditions:
Advanced Solid Tumor
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This study is testing a new medicine, SNV1521, for people with advanced cancers. The researchers want to find out if SNV1521 is safe, well-tolerated, and effective in treating solid tumors. They are i...
Eligibility Criteria
Inclusion
- Advanced or metastatic solid tumor malignancy
- Evaluable or Measurable disease (RECIST 1.1 Criteria).
- ECOG Performance Status 0 or 1.
- Life expectancy \> 3 months
Exclusion
- History of other malignancy within the past 2 years
- Prior diagnosis of Myelodysplastic syndrome or Acute Myeloid Leukemia
- Significant cardiovascular disease within 6 months
- Significant gastrointestinal disease
- HIV infection with a CD4+ T-cell count \< 200 cells/μL and/or a detectable viral load
- Liver dysfunction
Key Trial Info
Start Date :
February 23 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT06220864
Start Date
February 23 2024
End Date
December 1 2026
Last Update
March 13 2025
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Yale University
New Haven, Connecticut, United States, 06520
2
Thomas Jefferson University
Philadelphia, Pennsylvania, United States, 19144
3
Sarah Cannon Research Institute
Nashville, Tennessee, United States, 37203
4
The University of Texas M.D. Anderson Cancer Center
Houston, Texas, United States, 77030